Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/16/2025

First-Line Antihypertensive Agents for Smokers at Risk for Hypertension

Primary Recommendation: Thiazide-Like Diuretics

  • The American College of Cardiology recommends chlorthalidone as the superior first-line choice based on the strongest cardiovascular outcomes evidence, with amlodipine as the preferred alternative if thiazide diuretics are not tolerated 1, 2
  • The ALLHAT trial demonstrated chlorthalidone's superiority over lisinopril for stroke prevention (15% lower risk) and over amlodipine for heart failure prevention (38% lower risk) 1, 2

Alternative First-Line Options

  • The European Society of Cardiology suggests amlodipine 5-10 mg once daily as an equally effective alternative to thiazides for all cardiovascular events except heart failure 1, 2, 3
  • The American Heart Association recommends ACE inhibitors (e.g., lisinopril 10-40 mg once daily) or ARBs (e.g., losartan 50-100 mg once daily) as appropriate first-line options, particularly if the patient develops diabetes, chronic kidney disease, or albuminuria 4, 5, 3

Treatment Initiation Strategy

  • The American College of Cardiology recommends starting with single-agent therapy (chlorthalidone 12.5-25 mg once daily) for Stage 1 hypertension, and initiating with two first-line agents from different classes for Stage 2 hypertension 1, 2

Critical Smoking-Specific Considerations

  • The European Heart Journal emphasizes that smoking cessation is the single most effective measure for preventing major cardiovascular events and should be strongly recommended alongside pharmacotherapy 4
  • The American Heart Association notes that smoking affects ambulatory blood pressure by raising daily BP, and e-cigarettes can also increase blood pressure and should be avoided 4

Agents to Avoid as First-Line Therapy

  • The European Society of Cardiology advises that beta-blockers should NOT be used as first-line therapy in this patient population due to their lower efficacy for stroke prevention and higher discontinuation rates 7, 3
  • The American College of Cardiology recommends avoiding alpha-blockers as first-line therapy due to inferior cardiovascular disease prevention compared to thiazides 2, 7

Monitoring and Safety

  • The American Heart Association recommends monitoring potassium and renal function within 7-14 days after initiating thiazide diuretics, ACE inhibitors, or ARBs, then at least annually 1, 2
  • The European Society of Cardiology advises maintaining potassium >3.5 mmol/L when using thiazide diuretics to avoid increased ventricular ectopy 2

Common Pitfalls to Avoid

  • The American Journal of Kidney Diseases warns against combining ACE inhibitors with ARBs due to lack of added benefit and increased adverse events including hyperkalemia and acute kidney injury 5, 2
  • The American College of Cardiology recommends avoiding the use of hydrochlorothiazide when chlorthalidone is available, as chlorthalidone has superior outcomes data and longer duration of action 1, 2

REFERENCES

1

Hypertension Management Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2

Hypertension Management Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6

First-Line Treatment for Hypertension [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025